Connect with us

Business

'It's a joke': retail investors shocked as China halts Ant Group's IPO – Yahoo Canada Finance

Published

 on


GlobeNewswire

Global Technology Spending on Revenue Cycle Management Industry

Global Technology Spending on Revenue Cycle Management Market to Reach $52. 5 Billion by 2027. Amid the COVID-19 crisis, the global market for Technology Spending on Revenue Cycle Management estimated at US$36.New York, Nov. 04, 2020 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Global Technology Spending on Revenue Cycle Management Industry” – https://www.reportlinker.com/p05961182/?utm_source=GNW 1 Billion in the year 2020, is projected to reach a revised size of US$52.5 Billion by 2027, growing at aCAGR of 5.5% over the period 2020-2027. Integrated, one of the segments analyzed in the report, is projected to record 5.8% CAGR and reach US$40.4 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Standalone segment is readjusted to a revised 4.6% CAGR for the next 7-year period. The U.S. Market is Estimated at $10.7 Billion, While China is Forecast to Grow at 5.1% CAGR The Technology Spending on Revenue Cycle Management market in the U.S. is estimated at US$10.7 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$9.2 Billion by the year 2027 trailing a CAGR of 5.1% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.3% and 4.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.5% CAGR.We bring years of research experience to this 8th edition of our report. The 130-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed. Competitors identified in this market include, among others, * 3M Health Information Systems * Allscripts Healthcare Solutions, Inc. * Cerner Corporation * Computer Programs and Systems, Inc. (CPSI) * GE Healthcare * McKesson Corporation * Optum, Inc. * Vizient Inc. Read the full report: https://www.reportlinker.com/p05961182/?utm_source=GNW I. INTRODUCTION, METHODOLOGY & REPORT SCOPE II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW Global Competitor Market Shares Technology Spending on Revenue Cycle Management Competitor Market Share Scenario Worldwide (in %): 2019 & 2025 Impact of Covid-19 and a Looming Global Recession 2. FOCUS ON SELECT PLAYERS 3. MARKET TRENDS & DRIVERS 4. GLOBAL MARKET PERSPECTIVE Table 1: World Current & Future Analysis for Technology Spending on Revenue Cycle Management by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets – Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 Table 2: World Historic Review for Technology Spending on Revenue Cycle Management by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 3: World 15-Year Perspective for Technology Spending on Revenue Cycle Management by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027 Table 4: World Current & Future Analysis for Integrated by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets – Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 Table 5: World Historic Review for Integrated by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 6: World 15-Year Perspective for Integrated by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 Table 7: World Current & Future Analysis for Standalone by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets – Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 Table 8: World Historic Review for Standalone by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 9: World 15-Year Perspective for Standalone by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 III. MARKET ANALYSIS GEOGRAPHIC MARKET ANALYSIS UNITED STATES Market Facts & Figures US Technology Spending on Revenue Cycle Management Market Share (in %) by Company: 2019 & 2025 Market Analytics Table 10: USA Current & Future Analysis for Technology Spending on Revenue Cycle Management by Platform – Integrated and Standalone – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 11: USA Historic Review for Technology Spending on Revenue Cycle Management by Platform – Integrated and Standalone Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 12: USA 15-Year Perspective for Technology Spending on Revenue Cycle Management by Platform – Percentage Breakdown of Value Sales for Integrated and Standalone for the Years 2012, 2020 & 2027 CANADA Table 13: Canada Current & Future Analysis for Technology Spending on Revenue Cycle Management by Platform – Integrated and Standalone – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 14: Canada Historic Review for Technology Spending on Revenue Cycle Management by Platform – Integrated and Standalone Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 15: Canada 15-Year Perspective for Technology Spending on Revenue Cycle Management by Platform – Percentage Breakdown of Value Sales for Integrated and Standalone for the Years 2012, 2020 & 2027 JAPAN Table 16: Japan Current & Future Analysis for Technology Spending on Revenue Cycle Management by Platform – Integrated and Standalone – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 17: Japan Historic Review for Technology Spending on Revenue Cycle Management by Platform – Integrated and Standalone Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 18: Japan 15-Year Perspective for Technology Spending on Revenue Cycle Management by Platform – Percentage Breakdown of Value Sales for Integrated and Standalone for the Years 2012, 2020 & 2027 CHINA Table 19: China Current & Future Analysis for Technology Spending on Revenue Cycle Management by Platform – Integrated and Standalone – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 20: China Historic Review for Technology Spending on Revenue Cycle Management by Platform – Integrated and Standalone Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 21: China 15-Year Perspective for Technology Spending on Revenue Cycle Management by Platform – Percentage Breakdown of Value Sales for Integrated and Standalone for the Years 2012, 2020 & 2027 EUROPE Market Facts & Figures European Technology Spending on Revenue Cycle Management Market: Competitor Market Share Scenario (in %) for 2019 & 2025 Market Analytics Table 22: Europe Current & Future Analysis for Technology Spending on Revenue Cycle Management by Geographic Region – France, Germany, Italy, UK and Rest of Europe Markets – Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 Table 23: Europe Historic Review for Technology Spending on Revenue Cycle Management by Geographic Region – France, Germany, Italy, UK and Rest of Europe Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 24: Europe 15-Year Perspective for Technology Spending on Revenue Cycle Management by Geographic Region – Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027 Table 25: Europe Current & Future Analysis for Technology Spending on Revenue Cycle Management by Platform – Integrated and Standalone – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 26: Europe Historic Review for Technology Spending on Revenue Cycle Management by Platform – Integrated and Standalone Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 27: Europe 15-Year Perspective for Technology Spending on Revenue Cycle Management by Platform – Percentage Breakdown of Value Sales for Integrated and Standalone for the Years 2012, 2020 & 2027 FRANCE Table 28: France Current & Future Analysis for Technology Spending on Revenue Cycle Management by Platform – Integrated and Standalone – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 29: France Historic Review for Technology Spending on Revenue Cycle Management by Platform – Integrated and Standalone Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 30: France 15-Year Perspective for Technology Spending on Revenue Cycle Management by Platform – Percentage Breakdown of Value Sales for Integrated and Standalone for the Years 2012, 2020 & 2027 GERMANY Table 31: Germany Current & Future Analysis for Technology Spending on Revenue Cycle Management by Platform – Integrated and Standalone – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 32: Germany Historic Review for Technology Spending on Revenue Cycle Management by Platform – Integrated and Standalone Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 33: Germany 15-Year Perspective for Technology Spending on Revenue Cycle Management by Platform – Percentage Breakdown of Value Sales for Integrated and Standalone for the Years 2012, 2020 & 2027 ITALY Table 34: Italy Current & Future Analysis for Technology Spending on Revenue Cycle Management by Platform – Integrated and Standalone – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 35: Italy Historic Review for Technology Spending on Revenue Cycle Management by Platform – Integrated and Standalone Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 36: Italy 15-Year Perspective for Technology Spending on Revenue Cycle Management by Platform – Percentage Breakdown of Value Sales for Integrated and Standalone for the Years 2012, 2020 & 2027 UNITED KINGDOM Table 37: UK Current & Future Analysis for Technology Spending on Revenue Cycle Management by Platform – Integrated and Standalone – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 38: UK Historic Review for Technology Spending on Revenue Cycle Management by Platform – Integrated and Standalone Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 39: UK 15-Year Perspective for Technology Spending on Revenue Cycle Management by Platform – Percentage Breakdown of Value Sales for Integrated and Standalone for the Years 2012, 2020 & 2027 REST OF EUROPE Table 40: Rest of Europe Current & Future Analysis for Technology Spending on Revenue Cycle Management by Platform – Integrated and Standalone – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 41: Rest of Europe Historic Review for Technology Spending on Revenue Cycle Management by Platform – Integrated and Standalone Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 42: Rest of Europe 15-Year Perspective for Technology Spending on Revenue Cycle Management by Platform – Percentage Breakdown of Value Sales for Integrated and Standalone for the Years 2012, 2020 & 2027 ASIA-PACIFIC Table 43: Asia-Pacific Current & Future Analysis for Technology Spending on Revenue Cycle Management by Platform – Integrated and Standalone – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 44: Asia-Pacific Historic Review for Technology Spending on Revenue Cycle Management by Platform – Integrated and Standalone Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 45: Asia-Pacific 15-Year Perspective for Technology Spending on Revenue Cycle Management by Platform – Percentage Breakdown of Value Sales for Integrated and Standalone for the Years 2012, 2020 & 2027 REST OF WORLD Table 46: Rest of World Current & Future Analysis for Technology Spending on Revenue Cycle Management by Platform – Integrated and Standalone – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 Table 47: Rest of World Historic Review for Technology Spending on Revenue Cycle Management by Platform – Integrated and Standalone Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 Table 48: Rest of World 15-Year Perspective for Technology Spending on Revenue Cycle Management by Platform – Percentage Breakdown of Value Sales for Integrated and Standalone for the Years 2012, 2020 & 2027 IV. COMPETITION Total Companies Profiled: 46 Read the full report: https://www.reportlinker.com/p05961182/?utm_source=GNW About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place. __________________________ CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

Let’s block ads! (Why?)



Source link

Continue Reading

Business

Pfizer cuts COVID-19 vaccine delivery by half for 2020 due to supply chain issues – Global News

Published

 on


Pfizer has confirmed to Global News that it will be distributing half the amount of COVID-19 vaccines that it had originally proposed for 2020 due to supply chain issues.

In an emailed statement to Global News, the pharmaceutical company confirmed what was first reported by the Wall Street Journal, that it will be delivering up to 50 million doses of the COVID-19 vaccine by the end of 2020 worldwide, down from the 100 million doses previously promised.

Read more:
Canada’s review of Pfizer coronavirus vaccine will be completed ‘soon,’ health minister says

“Based on current projections we expect to produce globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses in 2021,” Pfizer said in a statement.

Pfizer said there are two reasons the number of doses expected has changed.

Story continues below advertisement

“For one, scaling up a vaccine at this pace is unprecedented, and we have made significant progress as we have moved forwards in the unknown,” the company said.

“Additionally, scale up of the raw material supply chain took longer than expected.”


Click to play video 'Coronavirus: Canadian officials expect Pfizer vaccine ‘likely’ to arrive first'



1:27
Coronavirus: Canadian officials expect Pfizer vaccine ‘likely’ to arrive first


Coronavirus: Canadian officials expect Pfizer vaccine ‘likely’ to arrive first

Pfizer also noted that results of its clinical trial were received later than expected.

The company said finished doses are currently being made at a “rapid pace.”

“We are confident in our ability to supply at a pace of approximately 1.3 billion doses by the end of 2021,” Pfizer said.

Pfizer had adjusted its supply outlook in 2020 from 100 million to 50 million in November in publicly available statements, but had promised up to 100 million doses as late as September.

Story continues below advertisement

Read more:
Britain approves Pfizer coronavirus vaccine for use, 1st in world to do so

The vaccine has been found to be 95 per cent effective against COVID-19 in recent tests, and the United Kingdom became the first country to approve the vaccine on Wednesday.

Canada is set to receive up to four million doses of Pfizer’s vaccine between January and March 2021, and will finish its review of the vaccine “soon,” according to Health Minister Patty Hajdu.

© 2020 Global News, a division of Corus Entertainment Inc.

Let’s block ads! (Why?)



Source link

Continue Reading

Business

11 new COVID cases reported in Nova Scotia Thursday – HalifaxToday.ca

Published

 on


NEWS RELEASE
COVID-19/HEALTH/WELLNESS
*************************
As of today, Dec. 3, Nova Scotia has 119 active cases of COVID-19. Eleven new cases were identified Wednesday, Dec. 2.

Nine of the new cases are in Central Zone. The other two cases are in Northern Zone.

“As we get closer to another weekend under tighter restrictions, I want to remind all Nova Scotians that we need to continue limiting our social contacts and travel so we can contain the virus,” said Premier Stephen McNeil. “We have the ability to slow the spread of COVID-19 in our province if we follow all the public health measures.”

Nova Scotia Health Authority’s labs completed 2,047 Nova Scotia tests on Dec. 2.

Yesterday there were 338 tests administered at the rapid-testing pop-up site in Halifax and 148 tests administered at the rapid-testing pop-up site in Wolfville. There were no positive test results identified at either site.

Since Oct. 1, Nova Scotia has completed 71,631 tests. There have been 254 positive COVID-19 cases and no deaths. No one is currently in hospital. Cases range in age from under 10 to over 70. One hundred and thirty-five cases are now resolved. Cumulative cases may change as data is updated in Panorama.

“It is important to recognize that although our cases numbers are not as high as we expected them to be, we continue to see new cases of COVID-19 every day,” said Dr. Robert Strang, Nova Scotia’s chief medical officer of health. “Now is not the time to let our guard down. Please do your part to slow the spread of this virus by continuing to follow all the public health measures and restrictions.”

Visit https://covid-self-assessment.novascotia.ca/ to do a self-assessment if in the past 48 hours you have had or you are currently experiencing:
— fever (i.e. chills/sweats) or cough (new or worsening)

Or:
Two or more of the following symptoms (new or worsening):
— sore throat
— runny nose/nasal congestion
— headache
— shortness of breath/difficulty breathing

Call 811 if you cannot access the online self-assessment or wish to speak with a nurse about your symptoms.

When a new case of COVID-19 is confirmed, public health works to identify and test people who may have come in close contact with that person. Those individuals who have been confirmed are being directed to self-isolate at home, away from the public, for 14 days.

Anyone who has travelled outside of Atlantic Canada must self-isolate for 14 days. As always, any Nova Scotian who develops symptoms of acute respiratory illness should limit their contact with others until they feel better.

It remains important for Nova Scotians to strictly adhere to the public health order and directives – practise good hand washing and other hygiene steps, maintain a physical distance when and where required. Wearing a non-medical mask is mandatory in most indoor public places.

Rules concerning interprovincial travel within Nova Scotia, New Brunswick, Prince Edward Island and Newfoundland and Labrador have changed. The premiers of all four Atlantic provinces are cautioning against non-essential travel into neighbouring provinces. Currently, all non-essential travel into Prince Edward Island, New Brunswick and Newfoundland and Labrador requires a 14-day self-isolation. All public health directives of each province must be followed. Under Nova Scotia’s Health Protection Act order, visitors from outside Atlantic Canada must self-isolate for 14 days unless they completed their self-isolation in another Atlantic province.

Nova Scotians can find accurate, up-to-date information, handwashing posters and fact sheets at https://novascotia.ca/coronavirus .

Businesses and other organizations can find information to help them safely reopen at https://novascotia.ca/reopening-nova-scotia .

Quick Facts:
— testing numbers are updated daily at https://novascotia.ca/coronavirus
— a state of emergency was declared under the Emergency Management Act on March 22 and extended to Dec. 13
— online booking for COVID-19 testing appointments is available for Nova Scotians getting a test at all primary assessment centres or at the IWK Health Centre in Halifax

Additional Resources:
Government of Canada: https://canada.ca/coronavirus

Government of Canada information line 1-833-784-4397 (toll-free)

The Mental Health Provincial Crisis Line is available 24/7 to anyone experiencing a mental health or addictions crisis, or someone concerned about them, by calling 1-888-429-8167 (toll-free)

Kids Help Phone is available 24/7 by calling 1-800-668-6868 (toll-free)

For help or information about domestic violence 24/7, call 1-855-225-0220 (toll-free)

For more information about COVID-19 testing and online booking, visit https://novascotia.ca/coronavirus/symptoms-and-testing/

The COVID-19 self-assessment is at https://covid-self-assessment.novascotia.ca/

*************************

Let’s block ads! (Why?)



Source link

Continue Reading

Business

Oil could close at highest price since March after OPEC+ news – Al Jazeera English

Published

 on


OPEC and Russia agreed to a modest output increase of 500,000 barrels per day from January onwards.

Oil prices on Thursday were on track to hit their highest closes since early March after sources said OPEC and Russia agreed to a modest output increase of 500,000 barrels per day (bpd) from January onwards.

The increase means the Organization of the Petroleum Exporting Countries (OPEC) and Russia, a group known as OPEC+, would move to cutting production by 7.2 million bpd, or seven percent of global demand from January, compared with current cuts of 7.7 million bpd.

The OPEC+ producers, however, failed to find a compromise on a broader and longer-term policy for the rest of next year.

Brent futures rose 63 cents, or 1.3 percent, to $48.88 a barrel by 1:01pm EST (18:01 EMT). US West Texas Intermediate (WTI) crude rose 49 cents, or 1.1 percent, to $45.77.

That puts both benchmarks on track to close at their highest levels since March 5 – before most countries imposed lockdowns to stop the spread of the coronavirus.

OPEC+ met on Thursday to work on policies for 2021 after talks earlier in the week reached no conclusion on how to tackle weak oil demand amid a new wave of coronavirus infections.

OPEC+ had been widely expected to roll over oil cuts of 7.7 million bpd, or eight percent of global supplies, at least until March 2021.

But after hopes for the speedy approval of COVID-19 vaccines spurred a rally in oil prices at the end of November – Brent futures gained 27 percent in November – some producers questioned the need to tighten oil policy.

Those higher prices in November prompted US producers to boost output for a third week in a row last week for the first time since June 2019, reaching 11.1 million bpd, according to government data.

“With US oil output on the rise, OPEC+ couldn’t allow the Americans to win market share at their expense,” said Edward Moya, senior market analyst at OANDA in New York.

The premiums of front-month Brent and WTI over the same month in 2022, meanwhile, reached their highest since February 2020, signalling future price uncertainty.

Four OPEC+ sources said the group would now gather every month to decide on output policies beyond January and monthly increases are unlikely to exceed 500,000 bpd.

Monthly meetings by OPEC+ will make price moves more volatile and complicate hedging by US oil producers.

Let’s block ads! (Why?)



Source link

Continue Reading

Trending